NA-1(also termed Tat-NR2B9c), a 20-mer peptide functioned as a PSD-95 inhibitor, has been assessed in stroke model macaques monkey and now advances into Phase 3 clinical trial2. This evidence concerns the gene DLG4 and stroke disorder.